1. Home
  2. HRMY vs HUBG Comparison

HRMY vs HUBG Comparison

Compare HRMY & HUBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • HUBG
  • Stock Information
  • Founded
  • HRMY 2017
  • HUBG 1971
  • Country
  • HRMY United States
  • HUBG United States
  • Employees
  • HRMY N/A
  • HUBG N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • HUBG Oil Refining/Marketing
  • Sector
  • HRMY Health Care
  • HUBG Consumer Discretionary
  • Exchange
  • HRMY Nasdaq
  • HUBG Nasdaq
  • Market Cap
  • HRMY 1.8B
  • HUBG 2.1B
  • IPO Year
  • HRMY 2020
  • HUBG 1996
  • Fundamental
  • Price
  • HRMY $34.94
  • HUBG $34.98
  • Analyst Decision
  • HRMY Strong Buy
  • HUBG Buy
  • Analyst Count
  • HRMY 9
  • HUBG 8
  • Target Price
  • HRMY $55.33
  • HUBG $41.89
  • AVG Volume (30 Days)
  • HRMY 627.0K
  • HUBG 589.2K
  • Earning Date
  • HRMY 08-05-2025
  • HUBG 07-31-2025
  • Dividend Yield
  • HRMY N/A
  • HUBG 1.44%
  • EPS Growth
  • HRMY 58.41
  • HUBG N/A
  • EPS
  • HRMY 3.10
  • HUBG 1.65
  • Revenue
  • HRMY $772,527,000.00
  • HUBG $3,781,266,000.00
  • Revenue This Year
  • HRMY $20.45
  • HUBG N/A
  • Revenue Next Year
  • HRMY $17.32
  • HUBG $6.49
  • P/E Ratio
  • HRMY $11.29
  • HUBG $21.04
  • Revenue Growth
  • HRMY 17.74
  • HUBG N/A
  • 52 Week Low
  • HRMY $26.47
  • HUBG $30.75
  • 52 Week High
  • HRMY $41.61
  • HUBG $53.21
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 50.27
  • HUBG 51.13
  • Support Level
  • HRMY $34.09
  • HUBG $32.46
  • Resistance Level
  • HRMY $36.09
  • HUBG $36.38
  • Average True Range (ATR)
  • HRMY 1.42
  • HUBG 1.19
  • MACD
  • HRMY -0.19
  • HUBG -0.13
  • Stochastic Oscillator
  • HRMY 46.42
  • HUBG 52.72

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About HUBG Hub Group Inc.

Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.

Share on Social Networks: